Literature DB >> 19962463

Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]).

Ameeth Vedre1, Hitinder S Gurm, James B Froehlich, Eva Kline-Rogers, Gilles Montalescot, Joel M Gore, David Brieger, Ann L Quill, Kim A Eagle.   

Abstract

Animal models of myocardial ischemia have demonstrated reduction in arrhythmias using statins. It was hypothesized that previous statin therapy before hospitalization might be associated with reductions of in-hospital arrhythmic events in patients with acute coronary syndromes. In this multinational, prospective, observational study (the Global Registry of Acute Coronary Events [GRACE]), data from 64,679 patients hospitalized for suspected acute coronary syndromes (from 1999 to 2007) were analyzed. The primary outcome of interest was in-hospital arrhythmic events in previous statin users compared with nonusers. The 2 primary end points were atrial fibrillation and the composite end point of ventricular tachycardia, ventricular fibrillation, and/or cardiac arrest. In-hospital death was also examined. Of the 64,679 patients, 17,636 (27%) had received previous statin therapy. Those taking statins had higher crude rates of histories of angina (69% vs 46%), diabetes (34% vs 22%), heart failure (15% vs 8.4%), hypertension (74% vs 58%), atrial fibrillation (9.3% vs 7.0%), and dyslipidemia (85% vs 35%). Patients previously taking statins were less likely to have in-hospital arrhythmias. In propensity-adjusted multivariable models, previous statin use was associated with a lower risk for ventricular tachycardia, ventricular fibrillation, or cardiac arrest (odds ratio 0.81, 95% confidence interval 0.72 to 0.96, p = 0.002); atrial fibrillation (odds ratio 0.81, 95% confidence interval 0.73 to 0.89, p <0.0001); and death (odds ratio 0.82, 95% confidence interval 0.70 to 0.95, p = 0.010). In conclusion, patients previously taking statins had a lower incidence of in-hospital arrhythmic events after acute coronary syndrome than those not previously taking statins. Our study suggests another possible benefit from appropriate primary and secondary prevention therapy with statins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962463     DOI: 10.1016/j.amjcard.2009.07.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Pleiotropic effects of the HMG-CoA reductase inhibitors.

Authors:  Christos G Mihos; Orlando Santana
Journal:  Int J Gen Med       Date:  2011-04-04

Review 2.  Pleiotropic effects of statins.

Authors:  Narasaraju Kavalipati; Jay Shah; Ananthraman Ramakrishan; Hardik Vasnawala
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

3.  Primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Outcomes and determinants of outcomes: A tertiary care center study from North India.

Authors:  Gajendra Dubey; Sunil Kumar Verma; Vinay Kumar Bahl
Journal:  Indian Heart J       Date:  2016-11-30

4.  Association of statin therapy with ventricular arrhythmias among patients with acute coronary syndrome.

Authors:  Sirin Apiyasawat; Piyamitr Sritara; Tachapong Ngarmukos; Charn Sriratanasathavorn; Piya Kasemsuwan
Journal:  Heart Asia       Date:  2013-03-11

5.  Statins therapy can reduce the risk of atrial fibrillation in patients with acute coronary syndrome: a meta-analysis.

Authors:  Xue Zhou; Jian-lin Du; Jia Yuan; Yun-qing Chen
Journal:  Int J Med Sci       Date:  2013-01-10       Impact factor: 3.738

6.  Impact of Prior Use of Four Preventive Medications on Outcomes in Patients Hospitalized for Acute Coronary Syndrome--Results from CPACS-2 Study.

Authors:  Min Li; Yubei Huang; Xin Du; Shenshen Li; Jiachao Ji; Anushka Patel; Runlin Gao; Yangfeng Wu
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

Review 7.  Anti-arrhythmic properties of non-antiarrhythmic medications.

Authors:  Emmanuel Ato Williams; Vincenzo Russo; Sergio Ceraso; Dhiraj Gupta; Richard Barrett-Jolley
Journal:  Pharmacol Res       Date:  2020-03-23       Impact factor: 7.658

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.